FDA Study Links Asthma Drug Montelukast to Neuropsychiatric Effects
Key Insights
An FDA study reveals that montelukast, commonly known as Singulair, significantly binds to brain receptors crucial for psychiatric function.
The research indicates montelukast can penetrate the brain, accumulating in regions associated with psychiatric effects, raising concerns about its impact.
Following numerous reports of neuropsychiatric episodes, the FDA added a black box warning in 2020, highlighting potential mental health risks like suicidal thoughts.
A recent study by the U.S. Food and Drug Administration (FDA) has established a link between the asthma (search) drug montelukast, known by the brand name Singulair, and severe mental health side effects, including suicidal ideation. The findings, presented at the American College of Toxicology meeting in Austin, Texas, highlight the drug's ability to bind to multiple brain receptors critical for psychiatric functioning.
Montelukast's Mechanism and Impact
Montelukast, since its launch in 1998, has been a widely prescribed alternative to inhalers for asthma (search) relief. However, concerns have grown over reports of neuropsychiatric episodes in patients. The FDA's research indicates that montelukast can cross the blood-brain barrier and accumulate in brain regions associated with psychiatric effects. Jessica Oliphant, a deputy director at FDA’s National Center for Toxicological Research, noted the "significant binding" of montelukast to brain receptors in laboratory tests.
FDA's Response and Expert Opinions
In 2020, the FDA added a black box warning to montelukast's prescribing label, cautioning about serious mental health risks. This decision followed thousands of adverse event reports, including suicides, linked to the drug. Julia Marschallinger and Ludwig Aigner from Austria’s Institute of Molecular Regenerative Medicine, whose research was cited by the FDA, confirmed the presence of significant montelukast quantities in the brain. They explained that the affected receptors govern mood, impulse control, cognition, and sleep.
Unanswered Questions and Future Research
While the research demonstrates montelukast's interaction with brain receptors, it does not definitively prove a direct causal link to harmful effects in individual patients. Further studies are needed to understand the specific mechanisms by which montelukast's brain binding leads to adverse effects and to identify individuals who may be particularly vulnerable. Marschallinger stated, "It’s definitely doing something that’s concerning,", underscoring the importance of continued investigation.